Health Guidance

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Many people today take health insurance coverage for granted; there are many people who do not even have coverage. The issue is over 46 million people who do not have any health insurance or dental insurance. When you look at these numbers it breaks down that one out of every six people have no medical or dental coverage. As you view this problem it’s happening to people all across the country.

The major issue facing medical insurance and dental insurance is the pros and cons of enforcing a universal coverage law that has been based on the research that many people across the states are uninsured young individuals, such as teenagers who are healthier individuals who don’t believe they need any coverage. Continue reading ‘Many Americans Cannot Afford Health Benefits’ »

Health care is one of the most important components in your life. Disease or illness can really mean a down turn in your life. The biggest asset we can have in life therefore is health. Health care is normally defined as the management or treatment of any health problem through the services that might be offered by medical, nursing, dental or any other related service. When you talk about the care of health, you are talking of all goods and services that are produced to improve on your health. They may be curative, preventative or even palliative solutions. A system of health care is one that is organized to give health services to a population or a group of people.

Health care can be for an individual or for a large group of people depending on how the systems are organized. Importance of health care cannot be overemphasized. In society, people are worried about the kinds of systems there are, to deal with issues of health. In developed countries, their systems are designed to cater for all people; whether poor or rich. However, the systems are lacking in regard to flaws. In developing countries, people usually take care of health as an individual thing and, if you do not have enough money, you might not get access to quality care. There are so many disparities and, some systems in certain countries are becoming worse; not able to deal with demand of health. Health is not a cheap affair, you have to have a good system if you want it to work for you. Governments have the responsibility to create or formulate policies that will favor people in this regard. Good systems of health can be erected by the top most leadership of a state.

Continue reading ‘Importance of Good Health Care’ »

Marijuana has long been used by different age groups for its intoxicating effects. They’re used for a wide variety of reasons-recreational, religious, medical and even for self-image purposes. Marijuana is the dried up leaves, stems and seeds of the Cannabis sativa flower. It can be smoked, eaten and used as an ingredient in food.

The dangers of marijuana will always be present, though like many things it depends on quantity and regularity. First of all, if smoked, it has five times the tar content of a cigarette and contains a lot of carcinogens since they don’t pass through a filter the way they do with cigarettes. Regular users often develop chronic bronchitis or severe coughs.

Even though marijuana isn’t physically addictive, it is psychologically addictive. Users start out in small doses, or as casual users, but as they continue their usage, it can get to a point where they find themselves using it alone and eventually it can become a habit. Some examples of reasons that weed addicts use are that they need it to do well in their creative fields of work such as writing, painting or composing music. Others say it helps them to treat their anxiety, insomnia and even improve their self-esteem. Continue reading ‘Dangers of Marijuana – Are the Concerns Exaggerated Or Are They Facts?’ »

Its a common issue people have, they need medical work done but the cost is far beyond what they can afford, options seem very limited for most people don’t they? Well, many people seem to be looking at Thailand to resolve these issues.

Some quick facts, Thailand’s medical treatment match’s America’s, Australia and British but it cost’s less then 1/3 the price. Dental work in Thailand is also the same, with the quality been equal to our western counterparts but the bill been far below.

There are many medical centers in Thailand who are happy to work on forign patients, this work can include but is not limited to Doctors, Dentists, Plastic Surgeons. I recently was reading a article about a woman who was loosing all her teeth due to a genetic disorder, in her home city of Sydney she was told it would cost in excess of $15, 000 to have fake teeth put in for her. Continue reading ‘Facts To Consider – Medical Work In Thailand’ »

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs. ( http://www.bharatbook.com/detail.asp?id=68637&rt=F-Hoffmann-La-Roche-Ltd-PharmaVitae-Profile.html )

Roche has invested roughly CHF190m ($183m) at two production sites to manufacture devices that will allow patients to self-administer a subcutaneous formulation of Herceptin (trastuzumab; Roche/Genentech/Chugai). Continue reading ‘Roche: novel Herceptin formulation promises greater convenience’ »

Incoming search terms:

• herceptin indian manufacturers

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

The report provides market landscape, competitive landscape and market trends information on four ophthalmic devices market categories – cataract surgery devices, refractive surgery devices, vision care, and ophthalmic diagnostic equipment. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.( http://www.bharatbook.com/detail.asp?id=133653&rt=The-Future-of-Ophthalmic-Devices-Market-Forecasts-and-Growth-Opportunities-to-2016-The-Vision-Care-Segment-Emerges-as-a-Key-Revenue-Generator.html )

The Global Ophthalmic Devices Market to Reach $28 billion by 2016The global ophthalmic devices market is forecast to reach $28 billion by 2016 with a Compound Annual Growth Rate (CAGR) of 2.5% from 2009-2016. The market is expected to be driven by a huge population suffering from vision problems, the availability of reimbursement for a majority of the devices and surgeries and the direct to consumer approach of the companies. The aging population is also an important growth driver for the market. The availability and accessibility of treatment for a majority of vision problems is also leading to increased patient demand and a subsequent growth in the market. This report provides key data, information and analysis on the global ophthalmic devices market.

The US to Continue to be the Biggest Ophthalmic Devices Market
The US is the biggest market for ophthalmic devices, contributing 26% towards the global market in 2009, and this contribution is expected to increase to 27% in 2016. The US ophthalmic devices market was valued at $6 billion in 2009 and is forecast to grow at a CAGR of 3.4% to reach $7.6 billion in 2016. The market is expected to be driven by the high prevalence of vision problems, the increasing contribution of employees and employers for vision care coverage and the availability and easy accessibility of the latest medical interventions for affected patients. Continue reading ‘Vision Care Market Remains The Largest Category In The Global Ophthalmic Devices Market’ »

Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias market fairly recently while others are pursuing late-phase development in this indication, hoping to exploit the commercial potential of patient subgroups underserved by existing treatment options. ( http://www.bharatbook.com/detail.asp?id=134190&rt=Pipeline-Insight-Leukemias-Underserved-patient-populations-offer-potential-for-market-growth.html ) Continue reading ‘Pipeline Insight Leukemias Underserved Patient Populations Offer Potential For Market Growth’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »